TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026

Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

Shangzhu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.